FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monoth
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few options to offer patients much-needed symptom improvement,
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
US approves first nasal spray for major depressive disorder, PTSD conditions
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Johnson & Johnson strikes $14.6bn deal for neuroscience biotech Intra-Cellular
Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical ...
Trump administration directs federal health agencies to pause communications
Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...
Trump administration pauses communication from CDC, other health agencies
The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.
BioPharma Dive10d
J&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...
RFK Jr. says he’ll keep making money on anti-vaccine lawsuits while in office
The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.
Health and Human Services secretary influences every aspect of America’s health
The secretary of Health and Human Services is a member of the president’s cabinet of advisers, appointed by the president with the advice and consent of the U.S. Senate. The secretary advises the ...
Pregnancy raises risks to mental health in MS patients, study says
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.